These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 21460410

  • 1. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
    Barakat GM, Nuwayri-Salti N, Kadi LN, Bitar KM, Al-Jaroudi WA, Bikhazi AB.
    Gen Physiol Biophys; 2011 Mar; 30(1):34-44. PubMed ID: 21460410
    [Abstract] [Full Text] [Related]

  • 2. Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts.
    Hantouche CM, Bitar KM, Nemer GM, Obeid MY, Kadi LN, Der-Boghossian AH, Bikhazi AB.
    Can J Physiol Pharmacol; 2010 Jan; 88(1):54-63. PubMed ID: 20130739
    [Abstract] [Full Text] [Related]

  • 3. Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts.
    Al Lafi SM, Artinian SB, Boutary SS, Zwainy NS, Bitar KM, Bikhazi AB.
    Can J Physiol Pharmacol; 2013 Oct; 91(10):830-8. PubMed ID: 24144054
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 5. Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.
    Artinian SB, Al Lafi SM, Boutary SS, Bitar KM, Zwainy NS, Bikhazi AB.
    Exp Diabetes Res; 2011 Nov 10; 2011():489708. PubMed ID: 21747829
    [Abstract] [Full Text] [Related]

  • 6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Nov 10; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 7. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC.
    J Control Release; 2009 Feb 10; 133(3):172-7. PubMed ID: 18977255
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 9. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ.
    Life Sci; 2013 Mar 21; 92(10):533-40. PubMed ID: 23357248
    [Abstract] [Full Text] [Related]

  • 10. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B.
    Diabetes Metab; 2012 Oct 21; 38(4):298-308. PubMed ID: 22672960
    [Abstract] [Full Text] [Related]

  • 11. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
    Ozyazgan S, Kutluata N, Afşar S, Ozdaş SB, Akkan AG.
    Pharmacology; 2005 Jun 21; 74(3):119-26. PubMed ID: 15746570
    [Abstract] [Full Text] [Related]

  • 12. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 21; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

  • 13. Cross-talk related to insulin and angiotensin II binding on myocardial remodelling in diabetic rat hearts.
    Maharsy WM, Kadi LN, Issa NG, Bitar KM, Der-Boghossian AH, Abrahamian R, Bikhazi AB.
    J Renin Angiotensin Aldosterone Syst; 2007 Jun 21; 8(2):59-65. PubMed ID: 17703431
    [Abstract] [Full Text] [Related]

  • 14. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor.
    Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A, Esbrit P, Valverde I, Villanueva-Peñacarrillo ML.
    J Cell Physiol; 2010 Nov 21; 225(2):585-92. PubMed ID: 20506394
    [Abstract] [Full Text] [Related]

  • 15. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
    Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M.
    Circulation; 2008 May 06; 117(18):2340-50. PubMed ID: 18427132
    [Abstract] [Full Text] [Related]

  • 16. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
    Lebovitz HE, Banerji MA.
    Diabetes Technol Ther; 2012 Jun 06; 14 Suppl 1():S43-50. PubMed ID: 22650224
    [Abstract] [Full Text] [Related]

  • 17. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E, Kim L, Choi JM, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park DI, Park CY.
    Metabolism; 2015 May 06; 64(5):633-41. PubMed ID: 25704082
    [Abstract] [Full Text] [Related]

  • 18. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.
    Diabetologia; 2002 Oct 06; 45(10):1410-5. PubMed ID: 12378382
    [Abstract] [Full Text] [Related]

  • 19. Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart.
    Karam CN, Nuwayri-Salti N, Usta JA, Zwainy DS, Abrahamian RE, Al Jaroudi WA, Baasisri MJ, Abdallah SM, Bitar KM, Bikhazi AB.
    Endothelium; 2005 Oct 06; 12(5-6):225-31. PubMed ID: 16410221
    [Abstract] [Full Text] [Related]

  • 20. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS.
    Cleve Clin J Med; 2009 Dec 06; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.